At a Glance
- Company: GeneDx Holdings (Nasdaq: WGS); Zevra Therapeutics (Nasdaq: ZVRA)
- Location: Gaithersburg, MD; Greenwood Village, CO
- Headline figures: Sponsored ExomeDx access for suspected NPC cases
- Focus area: Niemann-Pick disease type C genetic testing
- Next steps: Data integration into GeneDx Infinity dataset
What happened?
GeneDx announced a sponsored genetic testing program with Zevra Therapeutics on 10 March 2026 to provide no-cost ExomeDx sequencing for patients with suspected Niemann-Pick disease type C (NPC). The initiative removes financial barriers, accelerates diagnosis using GeneDx’s industry-leading exome test and feeds de-identified data into the GeneDx Infinity rare disease dataset.
Why does it matter?
NPC is a fatal neurodegenerative disease often misdiagnosed due to nonspecific symptoms; timely exome sequencing identifies NPC1/NPC2 variants in ~95% of cases, enabling earlier intervention and trial eligibility for Zevra’s pipeline. Program leverages world’s largest rare disease genomic dataset to refine NPC biology and patient identification.
Who’s behind it?
GeneDx leads rare disease diagnostics; Zevra develops NPC therapies. Chief Business Officer Lisa Gurry and Zevra CCO Joshua Schafer highlighted collaboration’s role in closing diagnostic gaps.
How was it achieved?
ExomeDx delivers comprehensive NPC analysis; program covers clinician-ordered tests for suspected cases. De-identified results enhance GeneDx Infinity AI, supporting faster future diagnoses and Zevra’s clinical development.
What’s next?
Immediate clinician enrollment; data aggregation accelerates NPC insights. Supports Zevra’s mission to advance NPC treatments through precision patient identification.
What are people saying?
Gurry: “Every day counts… clinicians reach answers faster.” Schafer: “Enhance access… timely clinical decision-making.”